Walter, the simple answer is that we do not know at the moment. We can reasonably suspect that AIMs are going to be key and we know that we have a patent application related to them. We know about existing relationships with three universities, and might infer that there could be others - at least on the genotyping front - from what the company has said publicly. Universites will undertake basic research irrespective of how this might result in products downstream, and however these are brought to market. Time will tell...
Market Data 
Markets 
AI
